Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. Enrollment and dose escalation is completed in a Phase 1 study of a second product candidate, SNS-314, in patients with advanced solid tumors. An MTD was not established and no responses have been observed. Sunesis is seeking to partner or license SNS-314 for further development. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements including without limitation statements related to the potential safety, efficacy and commercial potential of voreloxin; planned additional clinical testing and development efforts for voreloxin; and the timing of enrollment in the ongoing clinical trials of voreloxin. Words such as "anticipate," "remain on track, ""indicate," "suggest," "appears," "encouraging," "interim," "potential," "estimates," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' development activities for voreloxin, including enrollment and reporting of results, could be halted significantly or delayed for various reasons; the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval; the risk that preliminary data and trends may n
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015 Six startups from ... April 4-17 as part of the U.S.-Russia Innovation ... group of biotechnology startups to participate in the ... (UNN) and the University of Maryland (UMD) signed ... their respective universities in the biomedical industry in ...
(Date:4/23/2015)... 2015  Cryoport, Inc. (OTCBB: CYRX) ("Company"), the ... the life sciences industry, today announced that the ... within the animal husbandry market by signing a ... the shipment of equine semen for artificial insemination ... Animal husbandry is a multi-billion dollar ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) ... the device) in real time, and this data is ... provider of Machine to Machine (M2M) communications for the ... VADLink.com can be monitored by a patient’s ... flow below a minimum threshold, the patient can be ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Genomas(R), a,biomedical company advancing DNA-guided medicine and ... Phase I-II Small,Business Innovation Research (SBIR) Grant totaling ... Statin Safety and Efficacy," was,awarded by the National ... are the most prescribed drugs in the world. ...
... to Attend April Meeting,in St. Louis, DANBURY, ... (SBS) today announced its outstanding roster of,keynote speakers ... be held,April 6-10 at America,s Center in St. ... and biotech industries from around the world are,expected ...
Cached Biology Technology:3SBio Inc. Approves Share Repurchase Program 2Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy 2Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... PITTSBURGHCarnegie Mellon University,s John Kitchin was awarded $750,000 ... of Energy for developing new materials for producing ... was elated to hear that my research had been ... professor in Chemical Engineering at Carnegie Mellon. "This ...
... distinctive red soils could play a part in the formation ... off east coast beaches in summer., A QUT team of ... gives our iron-rich soil its red colour, reaches water to ... a foul smell, but also make our eyes sting, cause ...
... This release is available in German . ... decreased over recent decades. In fact, the number of beekeepers has ... the result of a study that has now been published by ... provided an overview of the problem of bee colony decline at ...
Cached Biology News:Carnegie Mellon's John Kitchin receives early career award 2Is iron from soil a factor in algal blooms? 2Fewer honey bee colonies and beekeepers throughout Europe 2Fewer honey bee colonies and beekeepers throughout Europe 3
... designed for stabilizing the coating biomolecules ... immunoassay development. It can stabilize ... and drying process and for long ... works as a blocking agent to ...
... The Freedom EVO Clinical is Tecans open ... to enhance quality, safety and performance in ... Safety is provided by flexible barcode reading ... to mention that the system complies with ...
... is one of the smallest thermal cyclers on ... of either the 0.5ml (20 samples) or 0.2ml ... Fast heating and cooling rate of 3.6C/sec ... high performance Fast track programming with new ...
... cycler, flexible on your protocols, easy on your ... high sample throughput instrument at a highly affordable ... format: The truly user-friendly fully interchangeable block system ... of seconds without the need of any tools ...
Biology Products: